Patent 9428535 was granted and assigned to Moderna Therapeutics on August, 2016 by the United States Patent and Trademark Office.
The present disclosure provides methods of increasing the level of a polypeptide of interest in a mammalian subject by administering a polynucleotide having one or more chemical modifications and a Protein:Cytokine ratio of greater than 100.